Healthcare Services

Blood Screening Market Industry Forecast Reflecting Growth To $5.93 Billion By 2030

May 26, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Blood Screening Market By 2030 Based On Its 2026 Value?

The blood stream infection testing market size has witnessed substantial growth in recent years. It is anticipated to increase from $8.49 billion in 2025 to $9.5 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.9%. The historical expansion of this market can be ascribed to elements such as increasing incidence of bloodstream infections, rising hospital-acquired infection rates, expansion of clinical microbiology laboratories, adoption of automated diagnostic instruments, and growing awareness of sepsis management.

The market for blood stream infection testing is projected to experience swift expansion over the coming years, with its size forecast to reach $14.71 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.6%. Factors driving this growth during the projection period include a heightened need for quick diagnostic results, the increasing use of molecular diagnostics within hospitals, the broadening scope of personalized infection management, increased financial outlays in sophisticated laboratory infrastructure, and the growing incorporation of AI-powered diagnostic instruments. Key trends anticipated for the forecast timeframe encompass the wider acceptance of rapid molecular diagnostic assays, an uptick in the deployment of automated blood culture systems, the progressive inclusion of antimicrobial susceptibility testing, an enlargement of multiplex pathogen detection panels, and a heightened emphasis on the prompt diagnosis of sepsis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9047&type=smp

What Core Drivers Are Transforming The Blood Screening Market?

The rising occurrence of infectious diseases is projected to stimulate the expansion of the blood stream infection testing market in the future. These diseases are defined as illnesses resulting from pathogenic microorganisms, such as bacteria, viruses, fungi, or parasites. The rates of infectious diseases are escalating due to several factors, including increased global travel, urbanization, climate change, antibiotic resistance, and gaps in vaccination coverage. Bloodstream infection testing is vital in managing infectious diseases for diagnosing and identifying pathogens responsible for sepsis and other severe infections, which enables targeted and effective treatment. For instance, in October 2024, the World Health Organization, a Switzerland-based international public health organization, reported that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, an increase from about 7.5 million in 2022, positioning tuberculosis as the leading infectious disease killer. Consequently, the growing prevalence of infectious diseases is a primary driver for the blood stream infection testing market.

What Are The Major Segment Categories Within The Blood Screening Market?

The blood screening market covered in this report is segmented –

1) By Product: Reagents And Kits, Instruments, Software And Services

2) By Technology: Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assays, Next-Generation Sequencing (NGS)

3) By End User: Blood Banks, Diagnostic Centers And Pathology Labs, Hospitals, Clinics, Ambulatory Surgical Centers (ASCs)

Subsegments:

1) By Reagents And Kits: Diagnostic Reagents, Testing Kits

2) By Instruments: Automated Analyzers, Manual Testing Equipment

3) By Software And Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Support And Consulting Services

What Trends Are Influencing The Future Of The Blood Screening Market?

Leading companies in the bloodstream infection testing market are concentrating on integrating advanced technologies, such as machine learning-powered host-response diagnostics, to improve rapid detection, support clinical decision-making, and potentially enhance patient management. Host-response diagnostics analyze a patient’s immune system through gene expression signatures in blood samples, utilizing artificial intelligence (AI)-derived algorithms to determine the presence, type, and probable severity of an infection in real time, which helps clinicians make quicker and more precise treatment decisions. For instance, in January 2025, Inflammatix Inc., a US-based molecular diagnostics company, obtained clearance from the US Food and Drug Administration for TriVerity, a machine-learning-based molecular blood test designed to assist in the swift evaluation of patients with suspected acute infections or sepsis. This test measures 29 immune-related mRNAs and provides AI-generated scores indicating the likelihood of bacterial infection, viral infection, and the risk of severe illness, with results typically available in about 30 minutes. TriVerity supports clinical decision-making by decreasing diagnostic uncertainty, facilitating timely targeted therapy, and helping to optimize hospital resource utilization when employed alongside standard clinical evaluation and laboratory findings.

Which Organizations Are Operating Within The Blood Screening Market?

Major companies operating in the blood screening market are Abbott Laboratories, Grifols S.A., Becton Dickinson and Company, F. Hoffmann-La Roche AG, bioMérieux S.A., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics Inc., Beckman Coulter Inc., Siemens Healthineers AG, DiaSorin S.p.A., Merck KGaA, PerkinElmer Inc., Bio-Techne Corporation, Roche Diagnostics GmbH, Danaher Corporation, Sysmex Corporation, GenMark Diagnostics Inc., QIAGEN N.V., Hologic Inc., Luminex Corporation, Trinity Biotech plc, Fujirebio Inc., OraSure Technologies Inc., Immunetics Inc., Cepheid Inc., Haemonetics Corporation, Verax Biomedical Inc.

Access The Complete Blood Screening Market Report:

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

Which Region Has The Strongest Presence In The Blood Screening Market?

North America was the largest region in the blood screening market in 2025. The regions covered in the blood screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Blood Screening Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=9047&type=smp

Browse Through More Reports Similar to the Global Blood Screening Market 2026, By The Business Research Company

Drug Screening Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-screening-global-market-report

Blood Culture Tests Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-culture-tests-global-market-report

Bleeding Disorder Testing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/bleeding-disorder-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795